The technology of this company based at the University of Valencia Science Park, based on the use of bacteriophages, focuses on the prevention, diagnosis and treatment of pathogenic bacteria, including human, animal and plant health. Also participated by the University of Valencia and the Respiralia Foundation, with this investment the company will expand its laboratory and staff
The startup Evolving Therapeutics, founded by sisters Pilar and Marisa Domingo-Calap and specialised in combating multi-resistant bacteria, has received an investment of €100,000 from Angels Capital, Juan Roig's investment company. This capital injection will allow the company to expand its laboratory located in the Science Park of the University of Valencia and increase its workforce, consolidating its growth and innovation capacity.
The company, accelerated by Lanzadera, develops a technology based on the use of bacteriophages (also known as phages), biological entities capable of specifically targeting pathogenic bacteria. Its approach covers the prevention, diagnosis and treatment of bacterial infections, with applications in human, animal and plant health. This versatility places the company at the forefront of the fight against antibiotic-resistant bacteria.
"It is necessary to promote biotechnology in Valencia, we have the capacity and motivation, but often the resources are not enough. In our case, having Angels is a step forward for growth, it will allow us to create a new laboratory and thus be able to expand our staff. In addition, we believe that it is a synergy between entities that will allow us to move forward while maintaining our social commitment", Pilar Domingo-Calap, Evolving Therapeutics
The University of Valencia and the Respiralia Foundation have minority stakes in the company. The collaboration with these institutions reinforces Evolving Therapeutics' commitment to scientific research and the development of effective solutions to a global public health problem.
"It is necessary to promote biotechnology in Valencia, we have the capacity and motivation, but often the resources are not enough. In our case, having Angels is a step forward for growth, it will allow us to create a new laboratory and thus be able to expand our staff. In addition, we believe that it is a synergy between entities that will allow us to move forward while maintaining our social commitment,", says Pilar Domingo-Calap, from Evolving Therapeutics.
Meanwhile, from Angels, its CEO, Pepe Peris, highlights the disruptive potential of the technology developed by the startup and its positive impact on public health: "Investing in biotech solutions such as those offered by Evolving Therapeutics is betting on a better future, Pilar and Marisa are an example of Valencia's ability to generate and retain talent, they are a source of inspiration".
Evolving Therapeutics
Evolving Therapeutics was founded in 2023 by sisters and doctors Pilar Domingo-Calap and Marisa Domingo-Calap, with the support of the University of Valencia and the Respiralia Foundation, a non-profit foundation for cystic fibrosis. It is a biotech startup focused on the development of innovative solutions against multidrug-resistant bacteria. Its bacteriophage-based technology offers sustainable and effective alternatives for the diagnosis, treatment and prevention of bacterial infections in human, animal and plant health.
Evolving Therapeutics' links with the Universitat de València have been key in the development of its technology. Through collaboration and knowledge transfer programmes, the startup has had access to advanced infrastructure and scientific talent, strengthening its capacity to innovate and respond to the challenges posed by antimicrobial resistance.
Marina de Empresas, founded in 2015 and promoted by Juan Roig, is made up of the EDEM business school, the Lanzadera accelerator and the Angels investment company, which aims to invest in entrepreneurial leaders to develop sustainable companies and connect them with investors.
Get to know the companies in the Parc
Don't miss our podcast La bombilla de Livermore with Marisa Domingo Calap, CEO of Evolving Therapeutics, and Luis Caballero, CTO of HYBRIMS
Recent Posts